Physician profile
Stephanie B Eckert
NPI 1306814736
$2,316.36
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $131 · 2021: $414 · 2022: $622 · 2023: $428 · 2024: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $735.15 | 2019-2024 | Liletta, Lo Loestrin Fe, Orilissa |
| Therapeuticsmd, INC. | $212.86 | 2019-2022 | |
| Organon LLC | $163.83 | 2021-2024 | Nexplanon |
| Coloplast Corp | $127.34 | 2023 | Altis |
| Mayne Pharma Commercial LLC | $114.21 | 2021-2024 | |
| Cumberland Pharmaceuticals, INC. | $111.11 | 2021-2023 | Kristalose |
| Amag Pharmaceuticals, INC. | $104.20 | 2019-2020 | |
| Exeltis, USA INC. | $92.42 | 2020-2023 | Slynd |
| Pfizer INC. | $73.95 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $54.13 | 2019-2023 | Gardasil 9 |
| Mylan Pharmaceuticals INC. | $53.11 | 2021-2022 | |
| Avion Pharmaceuticals | $52.29 | 2020-2021 | |
| Myovant Sciences INC. | $48.02 | 2021-2022 | |
| Sage Therapeutics, LLC | $46.98 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $31.38 | 2023 | Myfembree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.44 | 2024 | Veozah |
| Aspira Women'S Health INC | $29.16 | 2021-2023 | Ova1 |
| Meditrina | $23.67 | 2022 | |
| Minerva Surgical, INC | $23.26 | 2021 | |
| Evofem Biosciences, INC. | $22.36 | 2021 | |
| Urovant Sciences INC | $20.03 | 2022 | |
| Shield Therapeutics INC | $19.70 | 2023 | Accrufer |
| Amgen INC. | $18.12 | 2019 | |
| Daiichi Sankyo INC. | $18.12 | 2019 | |
| Boston Scientific Corporation | $17.11 | 2019 | |
| Duchesnay USA Incorporated | $17.00 | 2019 | |
| Scynexis, INC. | $15.92 | 2022 | |
| Hologic Sales and Service, LLC | $14.14 | 2019 | |
| Coopersurgical, INC. | $13.40 | 2024 | Paragard T 380a |
| Allergan, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Eckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.